Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

Fresolimumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer.

Cambridge: AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the ...

Artificial intelligence (AI)-aided analysis of pathology slides showed potential as a predictive biomarker for non-small cell ...

Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not ...

At ASCO, the stellar PFS data sparked speculation that Tagrisso will become the standard of care in this type of early lung ...

AstraZeneca Plc and Daiichi Sankyo Co. have voluntarily withdrawn an application for a lung cancer treatment in the European ...

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small ...

Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise ...

A home-based exercise program boosted exercise capacity and quality of life among patients after lung cancer surgery but did not improve self-reported physical function, a new study found.